Bhoor Singh Bhati, Medical Oncologist at AIIMS, New Delhi, shared a post on X:
“New HER2 ADC Shows Promise Beyond T-DM1 – But Can It Match T-DXd?”
- HER2+ mBC Update
- Phase 3 (N=224, China)
- Trastuzumab Pamirtecan (BNT323/DB-1303) vs T-DM1
- Significant PFS benefit → primary endpoint met
Why vs T-DM1, not T-DXd?
- Trial designed when T-DM1 was global 2L standard
- Regulatory path in China still required T-DM1 comparator
Next: HR+ mBC (DYNASTY-Breast02)
New HER2 ADC contender, but true test will be vs T-DXd.”
